- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05127707
Strategies to Reduce Addiction Stigma Among Health Professionals
November 8, 2021 updated by: Johns Hopkins Bloomberg School of Public Health
Effect of Exposure to Visual Campaigns and Narrative Vignettes on Addiction Stigma Among Health Professionals: A Randomized Experiment
The aim of this study was to evaluate the effects of exposure to stigma reduction message frames communicated by visual campaigns and narrative vignettes among a national sample of health professionals.
Study Overview
Status
Completed
Intervention / Treatment
- Behavioral: Words Matter - Visual Campaign
- Behavioral: Words Matter - Visual Campaign & Narrative Vignette (Messenger: Person with Opioid Use Disorder) Experimental: Words Matter - Visual Campaign & Narrative Vignette (Messenger: Clinician)
- Behavioral: Words Matter - Visual Campaign & Narrative Vignette (Messenger: Clinician)
- Behavioral: Words Matter - Visual Campaign & Narrative Vignette (Messenger: Health System Administrator)
- Behavioral: Medication Treatment for Opioid Use Disorder Works - Visual Campaign
- Behavioral: Medication Treatment for Opioid Use Disorder Works - Visual Campaign & Narrative Vignette (Messenger: Person with Opioid Use Disorder)
- Behavioral: Medication Treatment for Opioid Use Disorder Works - Visual Campaign & Narrative Vignette (Messenger: Clinician)
- Behavioral: Medication Treatment for Opioid Use Disorder Works - Visual Campaign & Narrative Vignette (Messenger: Health System Administrator)
Detailed Description
This randomized experiment evaluated the impact of exposure to message frames communicating the importance of non-stigmatizing language regarding addiction and the effectiveness of medication treatment for opioid use disorder delivered through a visual campaign alone or through a visual campaign in addition to a narrative vignette from the perspective of one of three messengers (a person with opioid use disorder, a clinician, or a health system leader) on attitudes toward people with opioid use disorder and medications for treating opioid use disorder among a national sample of health professionals.
Study Type
Interventional
Enrollment (Actual)
1842
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21205
- Johns Hopkins Bloomberg School of Public Health
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- employed as health professional in the United States, including clinicians (e.g., physicians, nurses, physician assistants, pharmacists, and optometrists), technicians and technologists (e.g., laboratory technologist or technician, emergency medical technician, paramedic, licensed practical or licensed vocational nurse, medical records or health information technician, etc.), health aids and assistants (e.g., nursing aide, home health aide, medical assistant, pharmacy aide, phlebotomist, etc.)
- participant in existing web-based survey panel (IPSOS's KnowledgeNetworks panel and partner opt-in panel)
Exclusion Criteria:
- not employed in health profession
- not able to complete experiment and survey in English
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: No exposure control group
This group was not exposed to any message frame.
|
|
|
Experimental: Words Matter - Visual Campaign
Participants randomized to this arm were exposed to a visual campaign communicating the importance of use of non-stigmatizing language regarding substance use disorder and opioid use disorder in clinical settings.
|
Visual campaign emphasizing the importance of using non-stigmatizing language related to substance use and opioid use disorder in clinical settings.
|
|
Experimental: Words Matter - Visual Campaign & Narrative Vignette (Messenger: Person with Opioid Use Disorder)
Participants randomized to this arm were exposed to a visual campaign communicating the importance of use of non-stigmatizing language regarding substance use disorder and opioid use disorder in clinical settings and a narrative vignette told from the perspective of a person with opioid use disorder.
|
Visual campaign emphasizing the importance of using non-stigmatizing language related to substance use and opioid use disorder in clinical settings combined with a narrative vignette told from the perspective of a person with opioid use disorder
|
|
Experimental: Words Matter - Visual Campaign & Narrative Vignette (Messenger: Clinician)
Participants randomized to this arm were exposed to a visual campaign communicating the importance of use of non-stigmatizing language regarding substance use disorder and opioid use disorder in clinical settings and a narrative vignette told from the perspective of a clinician.
|
Visual campaign emphasizing the importance of using non-stigmatizing language related to substance use and opioid use disorder in clinical settings combined with a narrative vignette told from the perspective of a clinician working with patients with opioid use disorder
|
|
Experimental: Words Matter - Visual Campaign & Narrative Vignette (Messenger: Health System Administrator)
Participants randomized to this arm were exposed to a visual campaign communicating the importance of use of non-stigmatizing language regarding substance use disorder and opioid use disorder in clinical settings and a narrative vignette told from the perspective of a health system administrator/leader.
|
Visual campaign emphasizing the importance of using non-stigmatizing language related to substance use and opioid use disorder in clinical settings combined with a narrative vignette told from the perspective of a health system administrator/leader
|
|
Experimental: Medication Treatment Works - Visual Campaign
Participants randomized to this arm were exposed to a visual campaign communicating the effectiveness of medications for treating opioid use disorder in saving lives.
|
Visual campaign emphasizing the effectiveness and value of medications to treat opioid use disorder in saving lives
|
|
Experimental: Medication Treatment Works - Visual Campaign & Narrative Vignette (Person with OUD)
Participants randomized to this arm were exposed to a visual campaign communicating the effectiveness of medications for treating opioid use disorder in saving lives and a narrative vignette told from the perspective of a person with opioid use disorder.
|
Visual campaign emphasizing the effectiveness and value of medications to treat opioid use disorder in saving lives combined with a narrative vignette told from the perspective of a person with opioid use disorder
|
|
Experimental: Medication Treatment Works - Visual Campaign & Narrative Vignette (Clinician)
Participants randomized to this arm were exposed to a visual campaign communicating the effectiveness of medications for treating opioid use disorder in saving lives and a narrative vignette told from the perspective of a clinician.
|
Visual campaign emphasizing the effectiveness and value of medications to treat opioid use disorder in saving lives combined with a narrative vignette told from the perspective of a clinician who treats people with opioid use disorder
|
|
Experimental: Medication Treatment Works - Visual Campaign & Narrative Vignette (Health System Administrator)
Participants randomized to this arm were exposed to a visual campaign communicating the effectiveness of medications for treating opioid use disorder in saving lives and a narrative vignette told from the perspective of a health system administrator/leader.
|
Visual campaign emphasizing the effectiveness and value of medications to treat opioid use disorder in saving lives combined with a narrative vignette told from the perspective of a health system administrator/leader
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Rating of willingness to have person with opioid use disorder marry into their family
Time Frame: Measured immediately post-exposure to message frame intervention
|
Item from the Social Distance Scale that measures one element of stigma (desire for social distance).
Measured on 5-point Likert scale with 5 indicating greater unwillingness and 1 indicating greater willingness to have a person with opioid use disorder marry into the family.
Measured via survey questionnaire.
|
Measured immediately post-exposure to message frame intervention
|
|
Rating of willingness to have person with opioid use disorder as a neighbor
Time Frame: Measured immediately post-exposure to message frame intervention
|
Item from the Social Distance Scale that measures one element of stigma (desire for social distance).
Measured on 5-point Likert scale with 5 indicating greater unwillingness and 1 indicating greater willingness to have a person with opioid use disorder as a neighbor.
Measured via survey questionnaire.
|
Measured immediately post-exposure to message frame intervention
|
|
Rating of agreement that opioid use disorder is a medical condition
Time Frame: Measured immediately post-exposure to message frame intervention
|
Rating of agreement with statement "Opioid use disorder is a chronic medical condition like diabetes mellitus" on 5-point Likert scale with 5 indicating strong disagreement and 1 indicating strong agreement.
Measured via survey questionnaire.
|
Measured immediately post-exposure to message frame intervention
|
|
Rating of agreement that individuals with opioid use disorder are to blame
Time Frame: Measured immediately post-exposure to message frame intervention
|
Rating of agreement with statement "Individuals with opioid use disorder only have themselves to blame for their problem" on 5-point Likert scale with 5 indicating strong disagreement and 1 indicating strong agreement.
Measured via survey questionnaire.
|
Measured immediately post-exposure to message frame intervention
|
|
Rating of support for increasing government spending on opioid use disorder treatment
Time Frame: Measured immediately post-exposure to message frame intervention
|
Rating of support for increasing government spending on treatment of opioid use disorder with 5 indicating strongly favoring and 1 indicating strongly opposing.
Measured via survey questionnaire.
|
Measured immediately post-exposure to message frame intervention
|
|
Feeling thermometer measure of warmth toward people with opioid use disorder
Time Frame: Measured immediately post-exposure to message frame intervention
|
Rating of warmth felt toward people with opioid use disorder with 0 indicating extremely cold and 100 indicating extremely warm.
Measured via survey questionnaire.
|
Measured immediately post-exposure to message frame intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Stigmatizing Language - Addict
Time Frame: Measured immediately post-exposure to message frame intervention
|
Rating of agreement that term "addict" appropriate in a clinical care setting with 1 indicating strongly agree (that term is appropriate) and 5 indicating strongly disagree (that term is appropriate).
Measured via survey questionnaire.
|
Measured immediately post-exposure to message frame intervention
|
|
Stigmatizing Language - Substance abuse
Time Frame: Measured immediately post-exposure to message frame intervention
|
Rating of agreement that term "substance abuse" appropriate in a clinical care setting with 1 indicating strongly agree (that term is appropriate) and 5 indicating strongly disagree (that term is appropriate).
Measured via survey questionnaire.
|
Measured immediately post-exposure to message frame intervention
|
|
Stigmatizing Language - dirty
Time Frame: Measured immediately post-exposure to message frame intervention
|
Rating of agreement that term "'dirty' in reference to the result from a drug test" appropriate in a clinical care setting with 1 indicating strongly agree (that term is appropriate) and 5 indicating strongly disagree (that term is appropriate).
Measured via survey questionnaire.
|
Measured immediately post-exposure to message frame intervention
|
|
Stigmatizing Language - clean
Time Frame: Measured immediately post-exposure to message frame intervention
|
Rating of agreement that term "'clean' in reference to the result from a drug test" appropriate in a clinical care setting with 1 indicating strongly agree (that term is appropriate) and 5 indicating strongly disagree (that term is appropriate).
Measured via survey questionnaire.
|
Measured immediately post-exposure to message frame intervention
|
|
Stigmatizing Language - addicted baby
Time Frame: Measured immediately post-exposure to message frame intervention
|
Rating of agreement that term "addicted baby" appropriate in a clinical care setting with 1 indicating strongly agree (that term is appropriate) and 5 indicating strongly disagree (that term is appropriate).
Measured via survey questionnaire.
|
Measured immediately post-exposure to message frame intervention
|
|
Stigmatizing Language - person with substance use disorder
Time Frame: Measured immediately post-exposure to message frame intervention
|
Rating of agreement that term "person with substance use disorder" appropriate in a clinical care setting with 1 indicating strongly agree (that term is appropriate) and 5 indicating strongly disagree (that term is appropriate).
Measured via survey questionnaire.
|
Measured immediately post-exposure to message frame intervention
|
|
Stigmatizing Language - substance use
Time Frame: Measured immediately post-exposure to message frame intervention
|
Rating of agreement that term "substance use" appropriate in a clinical care setting with 1 indicating strongly agree (that term is appropriate) and 5 indicating strongly disagree (that term is appropriate).
Measured via survey questionnaire.
|
Measured immediately post-exposure to message frame intervention
|
|
Stigmatizing Language - negative test result
Time Frame: Measured immediately post-exposure to message frame intervention
|
Rating of agreement that term "negative test result" appropriate in a clinical care setting with 1 indicating strongly agree (that term is appropriate) and 5 indicating strongly disagree (that term is appropriate).
Measured via survey questionnaire.
|
Measured immediately post-exposure to message frame intervention
|
|
Stigmatizing Language - positive test result
Time Frame: Measured immediately post-exposure to message frame intervention
|
Rating of agreement that term "positive test result" appropriate in a clinical care setting with 1 indicating strongly agree (that term is appropriate) and 5 indicating strongly disagree (that term is appropriate).
Measured via survey questionnaire.
|
Measured immediately post-exposure to message frame intervention
|
|
Stigmatizing Language - baby born with neonatal opioid withdrawal syndrome
Time Frame: Measured immediately post-exposure to message frame intervention
|
Rating of agreement that term "baby born with neonatal opioid withdrawal syndrome" appropriate in a clinical care setting with 1 indicating strongly agree (that term is appropriate) and 5 indicating strongly disagree (that term is appropriate).
Measured via survey questionnaire.
|
Measured immediately post-exposure to message frame intervention
|
|
Willingness to sign pledge committing to using non-stigmatizing language
Time Frame: Measured immediately post-exposure to message frame intervention
|
Binary (yes/no) measure of whether participant is willing to sign a pledge committing to using non-stigmatizing language related to substance use disorder in clinical settings.
Measured via survey questionnaire.
|
Measured immediately post-exposure to message frame intervention
|
|
Perception of opioid use disorder treatment effectiveness
Time Frame: Measured immediately post-exposure to message frame intervention
|
Participant perception of whether there is a treatment for opioid use disorder that is effective for a long period of time (three close-ended response options: yes, there is a treatment; no, there isn't such a treatment; don't know).
Measured via survey questionnaire.
|
Measured immediately post-exposure to message frame intervention
|
|
Rating of willingness to have person taking medication marry into their family
Time Frame: Measured immediately post-exposure to message frame intervention
|
Rating of willingness to have person taking medication to treat opioid use disorder marry into family.
Item from the Social Distance Scale that measures one element of stigma (desire for social distance).
Measured on 5-point Likert scale with 5 indicating greater unwillingness and 1 indicating greater willingness to have a person taking medication to treat opioid use disorder marry into the family.
Measured via survey questionnaire.
|
Measured immediately post-exposure to message frame intervention
|
|
Rating of willingness to have person taking medication marry as a neighbor
Time Frame: Measured immediately post-exposure to message frame intervention
|
Rating of willingness to have person taking medication to treat opioid use disorder as a neighbor.
Item from the Social Distance Scale that measures one element of stigma (desire for social distance).
Measured on 5-point Likert scale with 5 indicating greater unwillingness and 1 indicating greater willingness to have a person taking medication to treat opioid use disorder as a neighbor.
Measured via survey questionnaire.
|
Measured immediately post-exposure to message frame intervention
|
|
Rating of strength/weakness of person taking medication
Time Frame: Measured immediately post-exposure to message frame intervention
|
Rating of strength/weakness of person taking medication to treat opioid use disorder on 5-point Likert scale with 5 indicating strong and 1 indicating weak.
This is a semantic differential measure.
Measured via survey questionnaire.
|
Measured immediately post-exposure to message frame intervention
|
|
Rating of agreement that recovery is possible
Time Frame: Measured immediately post-exposure to message frame intervention
|
Rating of agreement with statement "Most people with opioid use disorder will, with medication treatment, get well and return to productive lives" on a 5-point Likert scale with 5 indicating strongly disagree and 1 indicating strongly agree.
Measured via survey questionnaire.
|
Measured immediately post-exposure to message frame intervention
|
|
Feeling thermometer measure of warmth toward people taking medication
Time Frame: Measured immediately post-exposure to message frame intervention
|
Rating of warmth felt toward people taking medication to treat opioid use disorder with 0 indicating extremely cold and 100 indicating extremely warm.
Measured via survey questionnaire.
|
Measured immediately post-exposure to message frame intervention
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Alene Kennedy-Hendricks, PhD, Johns Hopkins Bloomberg School of Public Health
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 13, 2020
Primary Completion (Actual)
November 30, 2020
Study Completion (Actual)
November 30, 2020
Study Registration Dates
First Submitted
October 28, 2021
First Submitted That Met QC Criteria
November 8, 2021
First Posted (Actual)
November 19, 2021
Study Record Updates
Last Update Posted (Actual)
November 19, 2021
Last Update Submitted That Met QC Criteria
November 8, 2021
Last Verified
November 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Chemically-Induced Disorders
- Pathologic Processes
- Narcotic-Related Disorders
- Substance-Related Disorders
- Disease
- Opioid-Related Disorders
- Physiological Effects of Drugs
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Narcotics
- Analgesics, Opioid
Other Study ID Numbers
- IRB14743
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.